LARKSPUR, Calif.–(BUSINESS WIRE)– Aulos Bioscience, an immuno-oncology firm working to revolutionize most cancers care via the event of probably best-in-class IL-2 therapeutics, at this time shared a Trials in Progress poster that’s being offered on the American Society of Medical Oncology (ASCO) 2022 Annual Assembly. The poster showcases the research design for the corporate’s first-in-human Section 1/2 trial of AU-007 that’s presently enrolling sufferers in Australia. AU-007 is a human monoclonal antibody computationally designed by Biolojic Design, with a extremely differentiated method to harnessing the facility of interleukin-2 (IL-2) to eradicate stable tumors.
